• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Quotient Limited (Amendment)

    2/21/23 4:47:13 PM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QTNT alert in real time by email
    SC 13D/A 1 d448193dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

    QUOTIENT LIMITED

    (Name of Issuer)

    Ordinary Shares, nil par value

    (Title of Class of Securities)

    G73268149

    (CUSIP Number)

    Dominick DeAlto

    Honeywell Capital Management LLC

    115 Tabor Road

    Morris Plains, NJ 07950

    (973) 975-8496

    with copies to:

    Sam Badawi

    Ropes & Gray LLP

    1211 Avenue of the Americas

    New York, NY 10036-8704

    (212) 596-9834

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    February 16, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. G73268149       Page 2 of 8

     

      (1)    

      Names of reporting persons

     

      Honeywell Capital Management LLC

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☒

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      OO

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      (6)  

      Citizenship or place or organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)     

      Sole voting power

     

         (8)   

      Shared voting power

     

      14,644 (1)

         (9)   

      Sole dispositive power

     

       (10)   

      Shared dispositive power

     

      14,644 (1)

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      14,644 (1)

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    (13)  

      Percent of class represented by amount in Row (11)

     

      0.07%(2)

    (14)  

      Type of reporting person (see instructions)

     

      OO

     

    (1)

    Includes 14,644 ordinary shares, nil par value (the “Ordinary Shares”) of Quotient Limited (the “Issuer”) issuable upon the exercise of currently exercisable warrants with an exercise price of $30.00 per Ordinary Share (the “Warrants”).

    (2)

    Based on (i) 4,035,013 Ordinary Shares reported outstanding as of February 2, 2023 in the Issuer’s Form 10-Q for the quarterly period ended December 31, 2022, plus (ii) 17,020,000 Ordinary Shares issued on February 16, 2023, as described in Item 4, plus (iii) 14,644 Ordinary Shares issuable upon the exercise of the Warrants.


    CUSIP No. G73268149       Page 3 of 8

     

      (1)    

      Names of reporting persons

     

      Honeywell International Inc. Master Retirement Trust

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☒

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      OO

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      (6)  

      Citizenship or place or organization

     

      New Jersey

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)     

      Sole voting power

     

         (8)   

      Shared voting power

     

      7,322(1)

         (9)   

      Sole dispositive power

     

       (10)   

      Shared dispositive power

     

      7,322(1)

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      7,322(1)

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    (13)  

      Percent of class represented by amount in Row (11)

     

      0.03%(2)

    (14)  

      Type of reporting person (see instructions)

     

      OO

     

    (1)

    Includes 7,322 Ordinary Shares issuable upon the exercise of the Warrants.

    (2)

    Based on (i) 4,035,013 Ordinary Shares reported outstanding as of February 2, 2023 in the Issuer’s Form 10-Q for the quarterly period ended December 31, 2022, plus (ii) 17,020,000 Ordinary Shares issued on February 16, 2023, as described in Item 4, plus (iii) 7,322 Ordinary Shares issuable upon the exercise of the Warrants.


    CUSIP No. G73268149       Page 4 of 8

     

      (1)    

      Names of reporting persons

     

      Honeywell Common Investment Fund

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☒

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      OO

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      (6)  

      Citizenship or place or organization

     

      United Kingdom

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)     

      Sole voting power

     

         (8)   

      Shared voting power

     

      7,322(1)

         (9)   

      Sole dispositive power

     

       (10)   

      Shared dispositive power

     

      7,322(1)

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      7,322(1)

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    (13)  

      Percent of class represented by amount in Row (11)

     

      0.03%(2)

    (14)  

      Type of reporting person (see instructions)

     

      OO

     

    (1)

    Includes 7,322 Ordinary Shares issuable upon the exercise of the Warrants.

    (2)

    Based on (i) 4,035,013 Ordinary Shares reported outstanding as of February 2, 2023 in the Issuer’s Form 10-Q for the quarterly period ended December 31, 2022, plus (ii) 17,020,000 Ordinary Shares issued on February 16, 2023, as described in Item 4, plus (iii) 7,322 Ordinary Shares issuable upon the exercise of the Warrants.


    CUSIP No. G73268149       Page 5 of 8

     

    This Amendment No. 1 (the “Amendment”) amends and supplements the Schedule 13D filed by the Reporting Persons on December 15, 2022 (the “Original Schedule 13D”) and, as amended and supplemented by this Amendment, the “Schedule 13D”), with respect to the Ordinary Shares. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.

     

    Item 4.

    PURPOSE OF TRANSACTION.

    Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows:

    As previously disclosed, on December 5, 2022, the Reporting Persons entered into a transaction support agreement with the Issuer and the other Consenting Noteholders (the “Original TSA”). The Transaction Support Agreement was amended and restated on January 9, 2023 (the “A&R TSA”) to update and modify certain steps effectuating the transactions pursuant to which the Issuer will undergo a comprehensive restructuring of its balance sheet (collectively, the “Transactions”) remove references to the potential creditor schemes of arrangement in England, enhance the diligence available for the benefit of the consenting noteholders, provide for automatic termination (rather than termination only after receipt of written notice) upon certain events, and reduce the threshold of approval necessary to extend certain milestones set forth in the A&R TSA. The A&R TSA is otherwise substantially the same as the Original TSA.

    On January 10, 2023, in accordance with the A&R TSA, the Issuer filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”). On February 15, 2023 the Bankruptcy Court confirmed the Issuer’s plan of reorganization (the “Bankruptcy Plan”) and on February 16, 2023, and in accordance with the terms of the Bankruptcy Plan, the Issuer, Newco, Finance Co., Quotient Holdings GP, LLC, a Delaware limited liability company and the general partner of Newco (the “GP”), Merger Co, each direct and indirect subsidiary of the Issuer and the Consenting Noteholders entered into a Master Transaction Agreement (the “Master Transaction Agreement”), and the Issuer, Newco and Finance Co entered into a Business and Asset Transfer Agreement (the “BTA”), and the Issuer effected the transactions contemplated by the Master Transaction Agreement and the BTA, emerged from bankruptcy protection, and the Bankruptcy Plan went effective.

    Pursuant to the A&R TSA, Bankruptcy Plan, the Master Transaction Agreement and the BTA, on February 16, 2023, a series of transactions occurred which resulted in the Convertible Notes and Senior Secured Notes being extinguished, the Issuer issuing 13,020,000 Ordinary Shares to Finance Co and 4,000,000 Ordinary Shares to Merger Co, resulting in Newco indirectly owning approximately 81% of the outstanding Common Shares of the Issuer, and all of the subsidiaries of the Issuer becoming indirect wholly-owned subsidiaries of Newco. The limited partnership interests in Newco are held by certain of the Consenting Noteholders. The A&R TSA, Bankruptcy Plan, and Master Transaction Agreement further provide that as soon as practicable following the effective date, the Issuer, Finance Co. and Merger Co will enter into a merger agreement that will result in the Issuer becoming a wholly-owned indirect subsidiary of Newco (the “Merger”). The Master Transaction Agreement provides that the parties thereto will cooperate as reasonably necessary or desirable to consummate the Merger as soon as possible. Upon completion of the Merger, the Issuer is expected to terminate the registration of its equity securities under the Securities Exchange Act of 1934, as amended.


    CUSIP No. G73268149       Page 6 of 8

     

    Honeywell Capital Management LLC, Honeywell International Inc. Master Retirement Trust, and Honeywell Common Investment Fund do not have the ability, directly or indirectly, to direct the voting or disposition of Ordinary Shares held by Newco.

    Following the consummation of the transactions that occurred on February 16, 2023, any “group” that may be deemed to have existed between the Reporting Persons and other Consenting Noteholders has been terminated.

    The foregoing descriptions of the A&R TSA, the Master Transaction Agreement and the BTA are summaries only, do not purport to be complete and are qualified in their entirety by reference to the full text of the A&R TSA (including the exhibits thereto), the Master Transaction Agreement and the BTA, copies of which are attached hereto as Exhibits 99.3, 99.4, and 99.5, respectively, and incorporated herein by reference.

     

    Item 5.

    INTEREST IN SECURITIES OF THE ISSUER.

    Item 5 of the Original Schedule 13D is hereby amended and restated as follows:

    The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Statement is incorporated by reference in its entirety into this Item 5.

    (a), (b), The percentage of Ordinary Shares beneficially owned by the Reporting Persons is based on (i) 4,035,013 Ordinary Shares reported outstanding as of February 2, 2023 in the Issuer’s Form 10-Q for the quarterly period ended December 31, 2022, plus (ii) 17,020,000 Ordinary Shares issued on February 16, 2023, as described in Item 4.

    (c) Except than as described in Item 4, the Reporting Persons have not effected transactions in the Ordinary Shares during the past sixty days.

    (d) No person other than the Reporting Persons are known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Ordinary Shares held by the Reporting Persons.

    (e) February 16, 2023.

     

    Item 6.

    CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

    Item 6 of the Original Schedule 13D is hereby amended and supplemented as follows:

    The information set forth in Items 4 and 5 is incorporated herein by reference.

    Other than as described in this Item 6 and Items 4 and 5, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 hereof and between such persons and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any other securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies, including any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities other than standard default and similar provisions contained in loan agreements.


    CUSIP No. G73268149       Page 7 of 8

     

    Item 7.

    MATERIALS TO BE FILED AS EXHIBITS.

    Item 7 of the Original Schedule 13D is hereby amended and supplemented as follows:

     

    Exhibit 99.3    Transaction Support Agreement, as amended and restated (incorporated by reference to Exhibit 10.1 attached to the Issuer’s Current Report on Form 8-K filed with the SEC on January 10, 2023).
    Exhibit 99.4    Master Transaction Agreement
    Exhibit 99.5   

    Business and Asset Transfer Agreement


    CUSIP No. G73268149       Page 8 of 8

     

    Signatures

    After reasonable inquiry and to the best knowledge and belief of the undersigned, such person certifies that the information set forth in this Statement with respect to such person is true, complete and correct.

    Date: February 21, 2023

     

    Honeywell Capital Management LLC
    BY:   /s/ Dominick DeAlto
    Name:   Dominick DeAlto
    Title:   VP and Chief Investment Officer
    Honeywell International Inc. Master Retirement Trust
    BY:   /s/ Dominick DeAlto
    Name:   Dominick DeAlto
    Title:   VP and Chief Investment Officer
    Honeywell Common Investment Fund
    BY:   /s/ Dominick DeAlto
    Name:   Dominick DeAlto
    Title:   VP and Chief Investment Officer
    Get the next $QTNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QTNT

    DatePrice TargetRatingAnalyst
    12/3/2021$4.00 → $3.50Neutral
    Goldman Sachs
    8/6/2021$5.00 → $4.50Neutral
    Goldman Sachs
    More analyst ratings

    $QTNT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Quotient Limited

      15-12G - Quotient Ltd (0001596946) (Filer)

      6/30/23 7:56:39 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Quotient Limited

      EFFECT - Quotient Ltd (0001596946) (Filer)

      6/30/23 12:15:07 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Quotient Limited

      EFFECT - Quotient Ltd (0001596946) (Filer)

      6/30/23 12:15:20 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman Sachs reiterated coverage on Quotient with a new price target

      Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $3.50 from $4.00 previously

      12/3/21 9:07:16 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Goldman Sachs reiterated coverage on Quotient with a new price target

      Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $4.50 from $5.00 previously

      8/6/21 8:50:59 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Goldman Sachs initiated coverage on Quotient with a new price target

      Goldman Sachs initiated coverage of Quotient with a rating of Neutral and set a new price target of $5.00

      6/3/21 6:30:51 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care